Citations

Mayo Clinic

Showing 10 of 108599 citations.

Treatment of Narcolepsy and other Hypersomnias of Central Origin
Wise, Merrill S. , Arand, Donna L., Auger, R. Robert , Brooks, Stephen N., Watson, Nathaniel F.

Sleep | February 5, 2017 | Volume: 30 | Issue: 12 | Pages: 1712-1727

10.1093/sleep/30.12.1712 | PMID 18246981 Get It

Practice Parameters for the Psychological and Behavioral Treatment of Insomnia: An Update. An American Academy of Sleep Medicine Report
Kramer, Milton, Alessi, Cathy , Friedman, Leah, Boehlecke, Brian, Brown, Terry , Coleman, Jack, Owens, Judith , Pancer, Jeffrey, Swick, Todd J. , Morgenthaler, Timothy I. , Kapur, Vishesh K. , Lee-Chiong, Teofilo L.

Sleep | February 5, 2017 | Volume: 29 | Issue: 11 | Pages: 1415-1419

10.1093/sleep/29.11.1415 Get It

Practice Parameters for the Medical Therapy of Obstructive Sleep Apnea
Kapen, Sheldon, Alessi, Cathy , Boehlecke, Brian, Brown, Terry , Coleman, Jack, Friedman, Leah, Owens, Judith , Pancer, Jeffrey, Swick, Todd J. , Morgenthaler, Timothy I. , Lee-Chiong, Teofilo L. , Kapur, Vishesh K.

Sleep | February 5, 2017 | Volume: 29 | Issue: 8 | Pages: 1031-1035

10.1093/sleep/29.8.1031 Get It

Practice Parameters for the Use of Autotitrating Continuous Positive Airway Pressure Devices for Titrating Pressures and Treating Adult Patients with Obstructive Sleep Apnea Syndrome: An Update for 2007
Aurora, R. Nisha , Brown, Terry , Zak, Rochelle , Alessi, Cathy , Boehlecke, Brian, Chesson, Andrew L., Friedman, Leah, Owens, Judith , Pancer, Jeffrey, Swick, Todd J. , Morgenthaler, Timothy I. , Kapur, Vishesh K. , Maganti, Rama

Sleep | February 5, 2017 | Volume: 31 | Issue: 1 | Pages: 141-147

10.1093/sleep/31.1.141 | PMID 18220088 Get It

A History of the Council of State Neurosurgical Societies
Zaidi, Hasan A. , Tumialán, Luis M. , Colen, Chaim B., Stroink, Ann R., Linskey, Mark E. , Schirmer, Clemens M. , Watridge, Clarence B. , Watridge, Clarence, Rosenow, Joshua M. , Schirmer, Clemens M

Neurosurgery | February 5, 2017 | Volume: 80 | Issue: 1 | Pages: 146-157

10.1093/neuros/nyw009 | PMID 28362890 Get It

Abstract As neurological surgery evolved into its own subspecialty early in the 20th century, a need arose to create an environment for communication and education among those surgeons working in this burgeoning surgical discipline. As the socioeconomic climate in health care began to change in the United States, an unforeseen need arose that was outside the scope of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, and Society of Neurological Surgeons. The capacity to understand and address the evolving socioeconomic landscape and to offer a platform for advocacy required a new entity. Grassroots efforts of neurosurgeons at the state level ultimately yielded a formal organization of state neurosurgical societies to fill this void by recognizing, understanding, and addressing socioeconomic factors affecting the practice of neurological surgery. This formal organization became the Council of State Neurosurgical Societies (CSNS). The CSNS provides a forum in which state societies can meet to identify, understand, and advocate for policies on behalf of organized neurosurgery. The purpose of this paper is to detail the history of the formation of the CSNS. By understanding this history and the need for the development of the CSNS, it is hoped that its evolving role as a voice for neurological surgeons in the modern era of health care will be made clear.
Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms: Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms Trial
Becske, Tibor , Brinjikji, Waleed , Potts, Matthew B. , Kallmes, David F. , Shapiro, Maksim , Moran, Christopher J. , McDougall, Cameron G. , Szikora, István , Woo, Henry H. , Siddiqui, Adnan H. , Albuquerque, Felipe C. , Saatçi, Işıl , Cekirge, Saruhan H., Berez, Aaron L., Cher, Daniel , Berentei, Zsolt, Nelson, Peter K. , Levy, Elad I. , Lanzino, Giuseppe , Lopes, Demetrius K. , Fiorella, David , Marosföi, Miklós , Siddiqui, Adnan H , Szikora, Istvan

Neurosurgery | February 5, 2017 | Volume: 80 | Issue: 1 | Pages: 40-48

10.1093/neuros/nyw014 | PMID 28362885 Get It

Abstract BACKGROUND: Early and mid-term safety and efficacy of aneurysm treatment with the Pipeline Embolization Device (PED) has been well demonstrated in prior studies. OBJECTIVE: To present 5-yr follow-up for patients treated in the Pipeline for Uncoilable or Failed Aneurysms clinical trial. METHODS: In our prospective, multicenter trial, 109 complex internal carotid artery (ICA) aneurysms in 107 subjects were treated with the PED. Patients were followed per a standardized protocol at 180 d and 1, 3, and 5 yr. Aneurysm occlusion, in-stent stenosis, modified Rankin Scale scores, and complications were recorded. RESULTS: The primary endpoint of complete aneurysm occlusion at 180 d (73.6%) was previously reported. Aneurysm occlusion for those patients with angiographic follow-up progressively increased over time to 86.8% (79/91), 93.4% (71/76), and 95.2% (60/63) at 1, 3, and 5 yr, respectively. Six aneurysms (5.7%) were retreated. New serious device-related events at 1, 3, and 5 yr were noted in 1% (1/96), 3.5% (3/85), and 0% (0/81) of subjects. There were 4 (3.7%) reported deaths in our trial. Seventy-eight (96.3%) of 81 patients with 5-yr clinical follow-up had modified Rankin Scale scores ≤2. No delayed neurological deaths or hemorrhagic or ischemic cerebrovascular events were reported beyond 6 mo. No recanalization of a previously occluded aneurysm was observed. CONCLUSION: Our 5-yr findings demonstrate that PED is a safe and effective treatment for large and giant wide-necked aneurysms of the intracranial ICA, with high rates of complete occlusion and low rates of delayed adverse events.
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
Tivnan, Amanda , Heilinger, Tatjana, Ramsey, Joanne M. , O’Connor, Gemma, Pokorny, Jenny L. , Stringer, Brett W. , Day, Bryan W. , Kim, Ella L., Lode, Holger N. , Cryan, Sally‐Ann , Sarkaria, Jann N. , Boyd, Andy , Kim, Ella, Prehn, Jochen H.M.

Oncotarget | February 4, 2017 | Volume: 8 | Issue: 10 | Pages: 16605-16620

10.18632/oncotarget.15073 | PMID 28178667 Get It

Defining disparities in liver transplantation: The devil is in the details
Hirose, Ryutaro , Heimbach, Julie K.

Liver Transplantation | February 4, 2017 | Volume: 23 | Issue: 4 | Pages: 557-558

10.1002/lt.24740 | PMID 28160412 Get It

The highly sensitized, high MELD, simultaneous liver‐kidney or status 1A heart‐liver transplant candidate
Taner, Timuçin

Clinical Liver Disease | February 4, 2017 | Volume: 9 | Issue: 1 | Pages: 18-20

10.1002/cld.608 | PMID 30992950 Get It

Aortic Waveform Analysis to Individualize Treatment in Heart Failure
Wohlfahrt, Peter , Melenovský, Vojtěch , Redfield, Margaret M. , Olson, Thomas P. , Lin, Grace , Hametner, Bernhard , Wassertheurer, Siegfried , Borlaug, Barry A. , Abdelmoneim, Sahar S. , Borlaug, Barry A , Melenovský, Vojtěch

Circulation: Heart Failure | February 4, 2017 | Volume: 10 | Issue: 2 | Pages: No page available

10.1161/circheartfailure.116.003516 | PMID 28159826 Get It

Background— Afterload reduction is a cornerstone in the management of patients with heart failure (HF) and reduced ejection fraction. However, arterial load and the effect of HF therapies on afterload might vary between individuals. Tailoring vasoactive medicines to patients with HF based upon better understanding of arterial afterload may enable better individualization of therapy. Methods and Results— Subjects with HF and reduced ejection fraction underwent aggressive titration of vasoactive HF therapies with assessment of central aortic waveforms analyzed using pulse wave, wave separation, and arterial reservoir models. Clinical response to treatment was assessed using the 6-minute walk test distance, which increased in 25 subjects and decreased or remained unchanged in 13. Subjects with improvement on therapy displayed higher aortic pressure wave pulsatility (central pulse pressure [PP], reflected pressure wave, and reservoir pressure) at study entry compared with subjects without improvement (all P <0.05). Parameters derived by the arterial analysis methods were strongly correlated with one another and displayed similar ability to predict improvement. Aortic pressure pulsatility significantly decreased in subjects with functional improvement, whereas no change was observed in patients without functional improvement ( P for interaction <0.05). These differences in arterial load at baseline and on therapy were not apparent from conventional brachial artery cuff pressure assessments. Conclusions— Increased aortic pressure wave pulsatility and greater decrease in pulsatility on treatment are associated with functional improvement in patients with HF and reduced ejection fraction receiving aggressive vasodilator titration. These differences are not identifiable using brachial cuff pressures. Central aortic waveform analysis may enable better individualization of vasoactive therapies in chronic HF and reduced ejection fraction. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00588692.